Overview

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Status:
Completed

Trial end date:
2020-02-16

Target enrollment:

Participant gender:

Summary

A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)

Phase:

Phase 3

Details

Lead Sponsor:

CymaBay Therapeutics, Inc.

Treatments:

Seladelpar
Ursodeoxycholic Acid